kreon 20000 v zarnās šķīstošās cietās kapsulas
viatris healthcare limited, ireland - pankreatīna pulveris - zarnās šķīstošā kapsula, cietā - 20000 v
kreon 35000 v zarnās šķīstošās cietās kapsulas
viatris healthcare limited, ireland - pankreatīna pulveris - zarnās šķīstošā kapsula, cietā - 35000 v
influvac tetra suspensija injekcijām pilnšļircē
viatris healthcare limited, ireland - gripas vakcīna (virsmas antigēns, inaktivēta) - suspensija injekcijām pilnšļircē
calafos 750 mg košļājamās tabletes
viatris limited, ireland - lantāns - košļājamā tablete - 750 mg
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiskie līdzekļi - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmoloģiskie līdzekļi - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.
duphaston 10 mg apvalkotās tabletes
viatris sia, latvia - didrogesterons - apvalkotā tablete - 10 mg
setlona 120/15 mikrogrami/24 stundās vaginālās ievadīšanas sistēma
viatris limited, ireland - etonogestrelum, ethinylestradiolum - vaginālās ievadīšanas sistēma - 120/15 mikrogrami/24 stundās
brufedol 40 mg/ml suspensija iekšķīgai lietošanai
viatris healthcare limited, ireland - ibuprofēns - suspensija iekšķīgai lietošanai - 40 mg/ml
fraxiparine 5700 sv anti-factor xa/0,6 ml šķīdums injekcijām
viatris healthcare limited, ireland - nadroparīna kalcija sāls - Šķīdums injekcijām - 5700 sv anti-factor xa/0.6 ml